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Abstract: Background: Current therapeutic strategies for advanced prostate cancer (PCa) are largely ineffective. Because aberrant DNA 
methylation associated with inappropriate gene-silencing is a common feature of PCa, DNA methylation inhibitors might constitute an al- 
ternative therapy. In this study we aimed to evaluate the anti-cancer properties of RG108, a novel non-nucleoside inhibitor of DNA 
methyltransferases (DNMT), in PCa cell lines. 
Methods: The anti-tumoral impact of RG108 in LNCaP, 22Rv1, DU145 and PC-3 cell lines was assessed through standard cell viability, 
apoptosis and cell cycle assays. Likewise, DNMT activity, DNMT1 expression and global levels of DNA methylation were evaluated in 
the same cell lines. The effectiveness of DNA demethylation was further assessed through the determination of promoter methylation and 
transcript levels of GSTP1, APC and RAR-/J2, by quantitative methylation-specific PCR and RT-PCR, respectively. 
Results: RG108 led to a significant dose and time dependent growth inhibition and apoptosis induction in LNCaP, 22Rv1 and DU145. 
LNCaP and 22Rv1 also displayed decreased DNMT activity, DNMT1 expression and global DNA methylation. Interestingly, chronic 
treatment with RG108 significantly decreased GSTP1, APC and RAR-/J2 promoter hypermethylation levels, although mRNA re- 
expression was only attained GSTP1 and APC. 
Conclusions: RG108 is an effective tumor growth suppressor in most PCa cell lines tested. This effect is likely mediated by reversion of 
aberrant DNA methylation affecting cancer related-genes epigenetically silenced in PCa. However, additional mechanism might underlie 
the anti-tumor effects of RG108. In vivo studies are now mandatory to confirm these promising results and evaluate the potential of this 
compound for PCa therapy. 
Keywords: Prostate cancer, RG108, DNA methyltransferases, proliferation, apoptosis. 
 
INTRODUCTION 
Prostate cancer (PCa) is the most common diagnosed malig- 
nancy in Western countries and one of the leading causes of cancer- 
related morbidity and mortality [1]. Although effective therapy is 
available for early-stage PCa, treatment of advanced disease is 
mainly ineffective and remains a clinical challenge. 
Androgen-deprivation therapy is widely used for locally ad- 
vanced and systemically spread PCa. However, most patients that 
initially respond to androgen deprivation therapy have  a median 
time to progression to castration-resistant disease of only 18-30 
months [2]. Therefore, investigation of new therapeutic strategies is 
urgently needed and should be based, ideally, on the acquired 
knowledge about PCa biology. Indeed, PCa is a complex and het- 
erogeneous disease where multiple genetic and epigenetic altera- 
tions interplay and contribute to its development and  progression 
[3]. The most widely known epigenetic change in PCa is aberrant 
DNA methylation, which may lead to altered expression of tumor 
suppressor genes and proto-oncogenes. In fact, there are more than 
50 genes reported to be silenced by promoter hypermethylation in 
PCa,  including  GSTP1,  APC,  RAR/J2,  RASSF1A,  and    CCND2, 
among others [4-6]. Remarkably, unlike genetic alterations, epige- 
netic changes are chemically reversible and numerous compounds 
have been reported to be effective against cancer cells by  inhibiting 
one or more components of the epigenetic machinery. Among these 
are the DNA methyltransferases inhibitors (DNMTi), of which 5- 
azacytidine (5-Aza-CR) and 5-aza-2´-deoxycytidine (5-Aza-dCR) 
are the most widely described [7]. Interestingly, 5-Aza-dCR was 
shown to have modest clinical activity against castration-resistant 
PCa and to inhibit prostate cancer progression in TRAMP mice [8, 
9]. However, the effectiveness of these compounds relies on its 
incorporation into DNA, which may result in substantial, dose- 
dependent cytotoxicity [10]. Owing to the toxicity of nucleoside 
analogs, emphasis has been placed in the discovery of new com- 
pounds that more directly target DNMTs. One of those  compounds 
is RG108, a non-nucleoside analogue of DNMT designed to target 
human DNMT1 at its active site. RG108 was shown to be effective 
in human colon cancer cells, in which it was capable of reactivating 
several tumor suppressors genes (e.g., p16), without affecting the 
methylation status of centromeric repeats [11, 12]. Importantly and 
contrarily to 5-Aza-dCR, the DNA  demethylating  activity of 
RG108 was not associated with high levels of citotoxicity [11, 12]. 
To the best of our knowledge, the anti-tumoral effect of this com- 
pound has not been explored in PCa. 
Thus, we sought to investigate the potential of RG108 as a 
growth inhibitor of PCa cells. For that purpose, the impact  of 
RG108 in cell viability, apoptosis and cell cycle of several PCa cell 
lines  was  assessed.  Furthermore,  the  inhibitory  effect  on DNMT 
   and  consequent  DNA  demethylation  activity  of  this  drug    were 
evaluated, along with the re-expression of genes known to be epi- 
genetically silenced in PCa. 
 
  
MATERIALS AND METHODS 
Prostate Cancer Cell Lines and Drug Preparation 
Prostate cancer cell lines PC-3 and LNCaP were kindly pro- 
vided by Prof. Ragnhild A. Lothe from the Department of Cancer 
Prevention at the Institute for Cancer Research, Oslo, Norway, 
DU145 was obtained from American Type Culture Collection 
(ATCC, Lockville, MD), and 22Rv1 cells were kindly provided by 
Dr. David Sidransky at the Johns Hopkins University School of 
Medicine, Baltimore, MD, USA. LNCaP and 22Rv1 cells were 
grown in RPMI 1640, DU145 cells were maintained in MEM and 
PC-3 cells were grown in 50% RPMI-50% F-12 medium (GIBCO). 
All basal culture media were supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (GIBCO). Cells were main- 
tained in an incubator at 37ºC with 5% CO2. All PCa cell  lines 
were karyotyped by G-banding (for validation purposes) and rou- 
tinely tested for Mycoplasma spp. contamination (PCR Myco- 
plasma Detection Set, Clontech Laboratories). RG108 was pur- 
chased from Tocris Bioscience (Bristol, UK), dissolved in DMSO 
(Sigma-Aldrich, St. Louis, MO, USA), and stored at -20ºC until 
further use. 5-Aza-dCR was obtained from Sigma (Sigma-Aldrich), 
dissolved in 50% acetic acid-50% PBS and stored at -20ºC. For 
control purposes, cell lines were exposed to the vehicles  of the 
drugs only (DMSO or 50% acetic acid-50% PBS). 
Viability Assay 
PCa cells were seeded at 1000 cells per well onto 96-well flat 
bottoned culture plates, allowed to adhere overnight  and treated 
with different RG108 concentrations (i.e., 50, 100 and 200 µM) for 
3 days (acute exposure) and 14 days (chronic exposure). Cell viabil- 
ity was then evaluated by MTT assay. Briefly, 0.5 mg/ml of MTT 
reagent [3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium 
bromide] was added to each well, and the plates were incubated in 
the dark for 3 hours at 37ºC. Formazan crystals were then dissolved 
in DMSO and absorbance was read at 540 nm in  a  microplate 
reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany), 
subtracting the background, at 630 nm. Three replicates were per- 
formed for each condition, and at least two independent experi- 
ments were carried out. 
Apoptosis Evaluation 
Evaluation of apoptosis was performed using APO Percentage 
apoptosis assay kit (Biocolor Ltd., Belfast, Northern Ireland) ac- 
cording to the manufacturer’s instructions. The assay was carried 
out using the same cell conditions as those of the MTT assay. 
Apoptotic cells were assessed at the end of the day 3 and 14 in a 
FLUOstar Omega microplate reader at 550 nm. 
Cell Cycle Analysis 
Cell cycle distribution of PCa cells was determined by flow 
cytometry. Briefly: 5x10
5 
harvested cells were fixed overnight  at 
4ºC  with  70%  cold  ethanol. After washing  with  cold  PBS,  cells 
were ressuspended in staining Propidium Iodide Solution (Cytognos 
S.L, Salamanca, Spain) and incubated for 30 minutes at room tem- 
perature. All cells were then measured on a Cytomics FC500 flow 
cytometer (Beckman Coulter, Fullerton, CA, USA) and analyzed 
using Modfit LT (Verity Software House, Inc, Topshan, Maine, 
USA). 
Real Time Quantitative PCR (qRT-PCR) 
RNA was extracted from cell lines using TRIzol® (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. First strand 
synthesis was performed using the high-capacity CDNA Reverse 
Transcription Kit from Applied Biosystems (Foster City, CA). Ex- 
pression of target genes (Ki67, CDKN1A, APC, GSTP1, RAR/J2, 
DNMT1, DNMT3a, DNMT3b) was quantified using Taqman ex- 
pression  assays,  purchased  as pre-developed  assays from Applied 
Biosystems and normalized to the expression of the GUSB house- 
keeping gene. 
Western Blot 
Proteins were extracted from whole-cell lysates using  RIPA 
lysis buffer (Santa Cruz Biotechnology, CA, USA) and subse- 
quently quantified using a Pierce BCA assay  (Thermo Scientific 
Inc., Bremen, Germany), according  to  the manufacturer’s   instruc- 
tions. Briefly, 30 µg of protein from each sample were separated 
using 4–20% Mini-PROTEAN® TGX™ Precast Gel at 300 V and 
subsequently blotted onto Protran nitrocelulose transfer  membranes 
(Whatman, Dassel, Germany). For immunodetection, membranes 
were incubated overnight at 4ºC with antibodies directed against 
DNMT1 at 1:1,000 and active Caspase-3 at 1:200 (Cell Signaling 
Technology, Danvers, MA). The Immun-Star WesternC Chemilu- 
minescent kit (Bio-Rad, Hercules, CA, USA) was used to develop 
the membranes which were then recorded with Amersham Hyper- 
film (GE Healthcare Buckinghamshire, UK). To ascertain equal 
loading of protein, the membranes were incubated with a mono- 
clonal mouse antibody against B-Actin (1:8,000, Sigma-Aldrich). 
Protein band intensities were determined using Quantity One soft- 
ware (Bio-Rad), by comparing the protein band intensity with the 
loading control (B-Actin). 
DNMT Activity/Inhibition Assay 
Nuclear extracts from vehicle and RG108 treated LNCaP, 
22Rv1 and DU145 were obtained using Nuclear Extract Kit (Active 
Motif, Rixensart, Belgium) as per the manufacture’s protocol. After 
protein quantification, 10µg of nuclear lysate from each sample was 
used to measure DNMT activity or inhibition with DNMT Activ- 
ity/Inhibition Assay Kit (Active Motif) according to the manufac- 
turer’s instructions. Absorbance was measured using FLUOstar 
Omega microplate reader, at 450 nm. All samples were analyzed in 
triplicate. 
Quantification of Global DNA Methylation 
Global DNA methylation was analyzed by the Imprint® Methy- 
lated DNA Quantification Kit (Sigma-Aldrich) according to the 
manufacturer’s instructions. DNA methylation status was compared 
with an artificially fully methylated DNA positive control. Absor- 
bance was measured using FLUOstar Omega microplate reader at 
450 nm. All samples were analyzed in triplicate. 
Quantitative Methylation Specific PCR (qMSP) 
Genomic DNA was extracted from cell lines using a standard 
technique comprising digestion with proteinase K (20mg/mL) in the 
presence of 10% SDS at 55ºC, followed by phenol-chloroform ex- 
traction and precipitation with 100% ethanol [13]. One  microgram 
of DNA was submitted to bisulfite modification using the EZ DNA 
Methylation-Gold™ Kit (Zymo Research, Orange, CA) following 
the manufacturer’s instructions. Bisulfite modified DNA was am- 
plified by qMSP using TaqMan technology [14]. Specific GSTP1, 
APC and RAR/J2 primers and TaqMan probes were designed using 
the Methyl Primer Express Software v1.0 (Applied Biosystems). /J- 
actin (ACTB) was used as an internal reference gene to  normalize 
for DNA input and all qMSP reactions were performed as previ- 
ously described [4]. Methylation levels for each sample were de- 
rived from calibration curves constructed using serial dilutions of 
bisulfite modified CpGenomeTM Universal Methylated DNA (Mil- 
lipore, Billerica, MA). GSTP1, APC and RAR2/J methylation levels 
were calculated after normalization for ACTB. 
Statistical Analysis 
One-way analysis of variance (ANOVA), with post-hoc Dun- 
net’s multiple comparison test when appropriate, was used to com- 
pare the results obtained in each parameter for the three different 
concentrations of RG108  and  the controls  (vehicle).  Analysis was 
  
performed with SPSS software for Windows version 19.0 (IBM- 
SPSS Inc Chigaco, IL) and statistical significance was  set at 
P<0.05. 
RESULTS 
RG108 Inhibits Cell Viability and Induces Apoptosis in Human 
PCa Cells 
To investigate the effects of the demethylating agent RG108 on 
cell viability, four human PCa cell lines, LNCaP, 22Rv1, DU145 
and PC-3 were exposed to three different concentrations of RG108, 
as wells as to the vehicle of this compound, DMSO. Cell viability 
was evaluated at days 0, 1, 2, 3, 7, 10 and 14. Acute exposure to 
RG108 resulted in a slight decrease in the number of viable cells 
(Fig. 1A). Regarding LNCaP, there was a significant decrease in 
cell viability  at the end  of the  second  day  when  treated  with 200 
µM of RG108 (P<0.04) compared to the vehicle. 22Rv1 showed a 
decrease in cell viability at day 1 when exposed to 50 and 200 µM 
of RG108 (P<0.04) and at the end of the third day when 100 and 
200 µM concentrations were applied (P<0.03). DU145 treated cells 
also suffered a slight reduction in viable cells on the first day with 
50 and 100 µM concentrations (P<0.02) and at day 3 when exposed 
to 200µM (P<0.002). 
As shown in (Fig. 1A), chronic exposure induced an impressive 
reduction in viable cells especially when the higher concentration of 
RG108 was used. LNCaP was the most sensitive cell line, since the 
inhibition of cell growth occurred for all the tested days at all the 
tested drug concentrations (P<0.002). LNCaP exposure to 200 µM 
RG108 during 14 days resulted in an 80% reduction in viable cells. 
22Rv1 also displayed a decrease in the number of viable cells in all 
days (7, 10, and 14) with 200 µM RG108 (P<0.004), being the 
reduction after 14 days of treatment of 50%, whereas DU145 only 
showed a decrease of 10% in cell viability in the last day with 100 
and 200 µM RG108 (P<0.004). RG108 appeared to have no effect 
on PC-3 cell viability. 
To corroborate the previous results, an analysis of molecular 
changes induced by RG108 was carried out by studying the quanti- 
tative expression of two genes involved in cell proliferation path- 
ways. Since the best results were obtained with 14 days of exposure 
and 200 µM of RG108, it was decided to evaluate gene expression 
under these conditions and at the concentration of 50 µM. The re- 
sults showed both induction of CDKN1A (P<0.020) and decrease of 
KI67 (P<0.045) mRNA levels of the RG108 treated cells when 
compared to the vehicle (Fig. 1B). 
To determine if the exposure to RG108 was capable of induce 
significant cell death, an apoptotic assay that detects the phosphati- 
dylserine transfer to the outside of the membrane was performed. 
Acute exposure to RG108 resulted in a significant increase in apop- 
tosis (Fig. 1C) for LNCaP with 100 and 200 µM (P<0.037) and for 
22Rv1 and DU145 with 100 µM (P:S0.002). Chronic treatment 
induced an augment in apoptosis (Fig. 1C) in LNCaP cells when 
treated with 100 µM (P<0.038) and DU145 when exposed  to  50 
and 200 µM (P<0.007). 
To confirm apoptosis at molecular level, the mRNA levels of 
CASP3 were evaluated. As the best results achieved with the apop- 
tosis assay were obtained after 14 days, only this time point was 
evaluated. Chronic treatment of LNCaP (100 µM), 22Rv1 (50 µM) 
and DU145 (200µM) resulted in significantly increased levels of 
CASP3 (P<0.029) (Fig. 1D). An increase of active Caspase 3 pro- 
tein levels’ was observed in all cell lines after drug exposure, 
namely in LNCaP and DU145 exposed to RG108 at 50 and 200 µM 
and in 22Rv1 when exposed to 100 µM (Fig. 1E). 
Since RG108 did not affect the cancer phenotype of PC-3 cell 
line, further studies were only performed in LNCaP, 22Rv1 and 
DU145 with 50 and 200 µM RG108. 
Cell cycle distribution was evaluated after 14 days of exposure 
to 50 and 200 µM RG108. There was no evidence of cell  cycle 
arrest in LNCaP and 22Rv1. However, DU145 presented a signifi- 
cant increase in the percentage of cells in G2/M transition for both 
concentrations of the compound (P<0.0001) (Fig.1F). 
RG108 Inhibits DNMT Activity and Expression in Human PCa 
Cells 
After exposing cells to 50 and 200 µM of RG108 for 14 days, 
nuclear extracts were obtained and DNMT activity was determined. 
As observed in (Fig. 2A), there was a significant reduction in 
DNMT activity (15%) for 22Rv1 with 50  µM  RG108 (P<0.003). 
For the remaining two cell lines a significant decrease in DNMT 
activity was not apparent, although LNCaP displayed a slight re- 
duction (13%). 
Subsequently, we determined whether decreased DNMT activ- 
ity correlated with decreased DNMT1, DNMT3a and DNMT3b 
mRNA levels. As expected, 22Rv1 and LNCaP showed decreased 
levels of DNMT1and DNMT3b compared to the vehicle, 22Rv1 cell 
line after exposure to 50 µM RG108 (P<0.013) and LNCaP after 
treatment with both tested concentrations (P<0.019). However, only 
22Rv1 demonstrated a significant reduction in DNMT3a mRNA 
levels (P<0.001) (Fig. 2B). Importantly, a reduction in DNMT1 
protein expression was displayed by both cell lines (Fig. 2C). 
RG108 Decreases Global DNA Methylation 
Once verified the ability of this compound to decrease DNMT 
activity and expression, the next step was to investigate the effect in 
global DNA methylation content. Since DU145 did not present a 
significant decrease in DNMT activity and expression, it was not 
further studied. To compare the effect of this demethylating agent 
with that of 5-Aza-dCR (a widely used demetylating drug), LNCaP 
and 22Rv1 cells were exposed to 1 and 5 µM of 5-Aza-dCR  during 
3 days. 
RG108 significantly decreased global DNA methylation in 
22Rv1 with 200 µM (approximately 5%, P<0.028), and in LNCaP 
cells (approximately 11% and 9% with 50 and 200 µM respec- 
tively, P<0.001) (Fig. 3A). In contrast, 5-Aza-dCR was able to 
reduce global DNA methylation in about 14% in LNCaP cells 
treated with 1 µM (P<0.001) and approximately 16% in 22Rv1 for 
both concentrations (P<0.001) (Fig. 3B). 
RG108 Causes Demethylation and Reactivation of Silenced 
Genes in Human PCa Cells 
To investigate the ability to demethylate and consequently in- 
duce the expression of specific genes, a panel of three genes (APC, 
GSTP1 and RAR/J2), previously reported to be silenced by promoter 
hypermethylation in PCa, was evaluated. 
Both LNCaP and 22Rv1 showed a decrease in  methylation 
levels of GSTP1 with 50 µM (P:S0.009) whereas solely 22Rv1 ex- 
hibited similar results with 200 µM (P<0.005) (Fig. 4A). However, 
only 22Rv1 demonstrated an increase in GSTP1 mRNA expression 
with 200 µM (P<0.001) (Fig. 4B). APC methylation levels were 
reduced in 22Rv1 with 50 µM of RG108 (P<0.005) (Fig. 4A), con- 
comitantly with the induction of mRNA expression of this gene 
(P<0.003) (Fig. 4B). Although a reduction in RAR/J2 methylation 
was observed in LNCaP with 200 µM (P<0.036) and in 22Rv1 with 
50 µM (P<0.003) of RG108 (Fig. 4A), the re-expression of this 
gene was not achieved (Fig. 4B). 
The results were also compared with those obtained with 5-aza- 
dCR. This compound was able to demethylate GSTP1 with 1 and   5 
µM in LNCaP and with 1µM in 22Rv1 (P<0.020). APC methyla- 
tion was only reduced in LNCaP cells exposed to 1 µM of 5-Aza- 
dCR (P<0.037). Concerning RAR/J2, no significant reduction in 
methylation levels was observed after exposure to 5-Aza-dCR (Fig. 
5). 
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Fig. (1). Effects of RG108 in viability, apoptosis and cell cycle of PCa cell lines. (A) Cell viability in LNCaP, 22Rv1, PC-3 and DU145, in the presence of 
RG108, at days 0, 1, 2, 3,7,10, and 14. (a) statistically significant differences were observed between vehicle and 50 µM RG108, (b) vehicle and 100 µM 
RG108 and (c) vehicle and 200 µM RG108. (B) mRNA expression of Ki67 and CDKN1A after 14 days of exposure to RG108. (C) Effect of acute and chronic 
RG108 exposure in apoptosis of PCa cell lines. (D) CASP3 mRNA expression and (E) active CASP3 protein expression after 14 days of exposure to RG108. 
(F) Cell cycle evaluation after 14 days of RG108 exposure. Data are presented as mean of three independent experiments ± s.d. 
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Fig. (2). Impact of RG108 on DNMT activity (A), in DNMTs mRNA expression (B), and DNMT1 protein expression after 14 days exposure to RG108. Data 
are shown as mean of three independent experiments ± s.d. 
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Fig. (3). Effect of RG108 (A) and 5-aza-CdR (B) on global DNA methylation. Data are presented as mean of three independent experiments ± s.d. 
  
 
 
Fig. (4). Impact of RG108 on demethylation (A) and re-expression (B) of GSTP1, APC and RAR/J2. Data are shown as mean of three independent experiments 
± s.d. 
 
 
DISCUSSION 
The gold standard treatment for hormone dependent PCa in- 
volves surgery, radiation or androgen deprivation therapy, depend- 
ing mainly on disease stage, whereas chemotherapy with docetaxel 
represents the main therapeutic option for castration-resistant PCa 
[15, 16]. In PCa, as well as in other cancers, the resistance of ma- 
lignant cells to anticancer agents remains the major cause of treat- 
ment failure. Therefore, new therapeutic options  are urgently 
needed.  Epigenetic  silencing  of  gene  expression,  especially  that 
mediated by promoter hypermethylation, plays an important role in 
the development and progression of PCa, as well as in the emer- 
gence of resistance to chemotherapy [17, 18]. Thus, DNMTs might 
constitute a valuable therapeutic target for PCa treatment. Reversal 
of DNA methylation with DNMTi has being widely studied in sev- 
eral cancers. In fact, two nucleoside analogs 5-azacytidine and 5- 
aza-2´-deoxycitidine have been already approved by US Food and 
Drug Administration (US FDA) for the treatment of myelodysplas- 
tic syndrome [19]. However, those two nucleoside analogs have 
demonstrated a limited efficacy in the treatment of solid   malignan- 
  
 
Fig. (5). Effect of 5-Aza-CdR on GSTP1, APC and RAR/J2 promoter methylation levels. Data are presented as mean of three independent experiments ± s.d. 
 
cies [20, 21]. Both for this reason and owing to their significant 
cytotoxicity, new epigenetic compounds must be explored for can- 
cer treatment. 
Herein, we present the first study on the anti-cancer effect of 
RG108, a non-nucleoside DNMTi, in PCa. The exposure of  PCa 
cell lines (LNCaP, 22Rv1 and DU145) to RG108 resulted in a sig- 
nificant decrease in cell viability, in a dose and time dependent 
manner, being the 200 µM concentration and 14 days (chronic) of 
exposure the best combination tested. Interestingly, these results 
emphasize the need to achieve sustained levels of the drug to ensure 
a prolonged anti-tumor effect, which is in line with current thera- 
peutic guidelines for 5-azacytidine and 5-aza-2´-deoxycitidine in 
myelodisplastic syndrome [22-24]. Moreover, RG108 induced cell 
death by apoptosis in LNCaP and DU145, and in the latter,  cell 
cycle arrest in G2/M was also depicted. Importantly, these results 
were confirmed at the molecular level with a decrease of KI67 tran- 
script levels and induction of CDKN1A and CASP3 mRNA expres- 
sion. Thus, the ability to disturb multiple regulators of cancer cell 
survival in these distinct PCa cells lines by RG108 was proven. 
Because these cell lines are phenotypically different and present 
diverse patterns of cell response to this drug, it is tempting to sug- 
gest that RG108 might be effective against PCa in vivo,  which is 
also characterized by substantial molecular heterogeneity [3]. 
Some previous studies have reported on the cellular prolifera- 
tion inhibitory effect of 5-aza-dCR in PCa cell lines [25-27]. In fact, 
5-aza-dCR induces p53 and p21Waf1/Cip1 expression which is 
associated with inhibition of cell proliferation and induction of 
apoptosis in LNCaP cells, independently of DNA methylation [28, 
29]. In this study we provide evidence that RG108 has similar ef- 
fects on the inhibition of tumor growth in PCa  cells. Considering 
that both 5-aza-dCR and RG108 are effective, the latter might be 
more appealing from a clinical standpoint, not only because RG108 
is a non-nucleoside (and thus may be less cytotoxic), but also be- 
cause it does not require active cell division to exert its functions 
[11]. 
Remarkably, we also demonstrated that RG108 was  able not 
only to inhibit DNMT activity, but also DNMT1, 3a and 3b mRNA 
expression, as well as DNMT1 protein expression in LNCaP and 
22Rv1 cells. This might justify the observed reversal in GSTP1 and 
APC promoter hypermethylation and associated restoration of gene 
expression. The ability of RG108 to demethylate GSTP1 is a very 
important finding since this gene, which is methylated in the vast 
majority of PCa, was recently suggested as a potential useful bio- 
marker for assessing DNMTi efficacy in PCa [30]. These results are 
also in accordance with the reported ability of RG108 to demethy- 
late tumor suppressor genes (e.g., p16) in HCT116 cell line [11]. It 
must be recalled, however, that demethylation is not synonymous of 
re-expression, as clearly demonstrated in our study for RAR/J2. 
Because epigenetic silencing of cancer-related genes is a more 
complex phenomenon, in which other mechanisms, such as histone 
post-translational modifications, are also involved [17],     combined 
therapies with histone deacetylase inhibitors might prove  to  be 
more effective. 
This study also showed that RG108 has a weaker demethylating 
effect compared to 5-aza-dCR, as three days exposure to the latter 
was able to more effectively reduce the levels of global DNA meth- 
ylation than RG108 at 14 days. Similar results were reported for 
HCT116 cells, which showed a reduction of 50% of cytosine meth- 
ylation levels when exposed to 5-Aza-dCR (after five days of incu- 
bation) and of only 30% when exposed to RG108 (after 15 days) 
[11]. The superior efficacy of 5aza-dCR might be due to its proper- 
ties as a cytidine analogue. Once incorporated into the DNA, 5aza- 
dCR covalently traps the DNMTs on the DNA by forming a suicide 
complex which can lead to a massive loss of DNA methylation, 
resulting in genome hypomethylation, which may predispose to 
genomic instability and foster neoplastic transformation of normal 
cells [23, 31]. RG108, on the other hand, directly blocks DNMT1 
activity [11], and may, thus, explain the less potent global DNA 
demethylation effect. This therapeutical disadvantage of RG108 
may, however, be compensated by a lesser degree of global hy- 
pomethylation, minimizing genomic instability and improving its 
toxicity and safety profile. 
Interestingly, several studies have proposed 5-Aza-dCR as an 
adjuvant to conventional therapy of PCa [25, 26, 32, 33]. Those 
studies demonstrated that 5-Aza-dCR could sensitize PCa cell lines 
to docetaxel, which is the first line therapy for castration-resistant 
PCa [25]. Likewise, 5-Aza-dCR might restore the expression of 
androgen receptor in PC-3 cell line, and the combined treatment 
with bicalutamide demonstrated a synergistic effect in repressing 
tumor growth in xenograft mice [32].  Remarkably, bicalutamide 
was recently associated with higher DNMT3a and DNMT3b ex- 
pression, potentiating the up-regulation of truncated androgen re- 
ceptor isoforms and therefore the castration resistant  phenotype 
[33]. However, when cells were exposed to 5-Aza-dCR, there was a 
decrease in DNMT activity and a consequent decline in the devel- 
opment of the castration-resistant phenotype [33]. Because  RG108 
is able to modify the phenotype of PCa cells and the catalytic do- 
main of the four DNMTs is highly conserved, predicting similar 
interactions of those enzymes with RG108, it would be interesting 
to evaluate the possible synergistic action between RG108 and con- 
ventional PCa therapy. Moreover, based on the promising results 
from this study, further experiments should be conducted to inves- 
tigate the cellular pathways involved in RG108 response. Compar- 
ing these cellular pathways with those involved in 5-Aza-dCR re- 
sponse might provide valuable information concerning PCa cells 
biology and illuminate the different mechanisms of action of these 
compounds. 
CONCLUSIONS 
The demethylating agent RG108 demonstrated the ability to 
reduce cell viability, induce cellular death by apoptosis, and de- 
crease DNMT  activity and DNMT1  expression in PCa cells.    Fur- 
  
thermore, it was able to decrease promoter hypermethylation levels 
and induce re-expression of genes known to be epigenetically si- 
lenced in PCa. Because RG108 performed better in chronic expo- 
sure (14 days) at 200 µM concentration, further studies should be 
conducted with these conditions to further assess the promising role 
of RG108 as a valuable tool for PCa therapy. 
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